| Normal Healthy |
| 5345- | , | Effect of ajoene, the major antiplatelet compound from garlic, on platelet thrombus formation |
| - | in-vitro, | Nor, | NA |
| 4113- | , | Post-exposure Effects of PEMF on ROS levels in H2O2-treated Glioblastoma Cell Line |
| - | in-vitro, | Nor, | U87MG |
| 4442- | , | Anticancer and Hepatoprotective Role of Selenium Nanoparticles against |
| - | in-vivo, | Liver, | HepG2 | - | NA, | Nor, | NA |
| 6478- | 1,8-Cin, | The Combination of Amoxicillin and 1,8-Cineole Improves the Bioavailability and the Therapeutic Effect of Amoxicillin in a Rabbit Model |
| - | in-vivo, | Nor, | NA |
| 6477- | 1,8-Cin, | Protective effect of 1, 8-cineole (eucalyptol) against lead-induced liver injury by ameliorating oxidative stress and inflammation and modulating TLR4/MyD88/NF-κB signaling |
| - | in-vivo, | Nor, | NA |
| 6474- | 1,8-Cin, | Molecular Docking Identifies 1,8-Cineole (Eucalyptol) as A Novel PPARγ Agonist That Alleviates Colon Inflammation |
| - | in-vitro, | Nor, | HT29 | - | in-vivo, | Nor, | NA | - | in-vivo, | IBD, | NA |
| 6472- | 1,8-Cin, | Protective Effects of 1,8-Cineole Microcapsules Against Inflammation and Gut Microbiota Imbalance Associated Weight Loss Induced by Heat Stress in Broiler Chicken |
| - | in-vivo, | Nor, | NA |
| 6471- | 1,8-Cin, | The Effect of 1,8-Cineole Inhalation on Preoperative Anxiety: A Randomized Clinical Trial |
| - | Trial, | Nor, | NA |
| 6469- | 1,8-Cin, | Pharmacokinetic Studies of the Fragrance Compound 1,8-Cineol in Humans during Inhalation |
| - | Human, | Nor, | NA |
| 6468- | 1,8-Cin, | Inhibitory activity of 1,8-cineol (eucalyptol) on cytokine production in cultured human lymphocytes and monocytes |
| - | in-vitro, | Nor, | NA |
| 6467- | 1,8-Cin, | Evaluation of in vitro anticancer activity of 1,8-Cineole-containing n-hexane extract of Callistemon citrinus (Curtis) Skeels plant and its apoptotic potential |
| - | in-vitro, | Melanoma, | A431 | - | in-vitro, | OS, | MG63 | - | in-vitro, | Nor, | HaCaT |
| 6470- | 1,8-Cin, | Determination of orally administered 1,8-Cineol in nasal polyp tissues from chronic rhinosinusitis patients using gas chromatography: mass spectrometry |
| - | Human, | Nor, | NA |
| 2326- | 2DG, | Caloric Restriction Mimetic 2-Deoxyglucose Alleviated Inflammatory Lung Injury via Suppressing Nuclear Pyruvate Kinase M2–Signal Transducer and Activator of Transcription 3 Pathway |
| - | in-vivo, | Nor, | NA |
| 5272- | 3BP, | The efficacy of the anticancer 3-bromopyruvate is potentiated by antimycin and menadione by unbalancing mitochondrial ROS production and disposal in U118 glioblastoma cells |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | Nor, | HEK293 |
| 3538- | 5-HTP, | Oral Administration of 5-Hydroxytryptophan Restores Gut Microbiota Dysbiosis in a Mouse Model of Depression |
| - | in-vivo, | Nor, | NA |
| 5308- | 5-HTP, | The Relationship Between Serotonin and 5-HTP |
| - | Review, | Nor, | NA |
| 5302- | 5-HTP, | Hippocampal ischaemia from accidental 5-Hydroxytryptophan (5-HTP) overdose case report |
| - | Case Report, | Nor, | NA |
| 5310- | 5-HTP, | 5-Hydroxytryptophan toxicity successfully treated by haemodialysis in a dog |
| - | Case Report, | Nor, | NA |
| 5295- | 5-HTP, | Safety of 5-hydroxy-L-tryptophan |
| - | in-vivo, | Nor, | NA |
| 5294- | 5-HTP, | Eosinophilia-myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophan |
| - | in-vivo, | Nor, | NA |
| 5291- | 5-HTP, | Kinetics of l-5-hydroxytryptophan in healthy subjects |
| - | in-vivo, | Nor, | NA |
| 5290- | 5-HTP, | Placebo-controlled comparison of three dose-regimens of 5-hydroxytryptophan challenge test in healthy volunteers |
| - | in-vivo, | Nor, | NA |
| 5300- | 5-HTP, | The Serotonin Syndrome: From Molecular Mechanisms to Clinical Practice |
| - | Review, | Nor, | NA |
| 5307- | 5-HTP, | 5-Hydroxytryptophan toxicosis in dogs: 1989-1999 |
| - | Case Report, | Nor, | NA |
| 5305- | 5-HTP, | An Investigation of the Cause of the Eosinophilia–Myalgia Syndrome Associated with Tryptophan Use |
| - | Review, | Nor, | NA |
| 5313- | acet, | Pharmacological hypotheses: Is acetaminophen selective in its cyclooxygenase inhibition? |
| - | Review, | Nor, | NA |
| 5461- | AF, | Dual inhibition of thioredoxin reductase and proteasome is required for auranofin-induced paraptosis in breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 5457- | AF, | Clinical pharmacokinetics of oral and injectable gold compounds |
| - | Human, | Nor, | NA |
| 5456- | AF, | Phase I Clinical Trial Results of Auranofin, a Novel Antiparasitic Agent |
| - | Trial, | Nor, | NA |
| 5442- | AG, | Ome, | Effects of astragaloside IV on the pharmacokinetics of omeprazole in rats |
| - | in-vivo, | Nor, | NA |
| 5443- | AG, | Pharmacokinetics and tolerance of toal astragalosides after intravenous infusion of astragalosides injection in healthy Chinese volunteers |
| - | Human, | Nor, | NA |
| 1097- | AG, | Astragalus Inhibits Epithelial-to-Mesenchymal Transition of Peritoneal Mesothelial Cells by Down-Regulating β-Catenin |
| - | in-vitro, | Nor, | HMrSV5 | - | in-vivo, | NA, | NA |
| 359- | AgNPs, | Anti-cancer & anti-metastasis properties of bioorganic-capped silver nanoparticles fabricated from Juniperus chinensis extract against lung cancer cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HEK293 |
| 391- | AgNPs, | Silver nanoparticles inhibit VEGF-and IL-1β-induced vascular permeability via Src dependent pathway in porcine retinal endothelial cells |
| - | in-vitro, | Nor, | NA |
| 1406- | AgNPs, | The antioxidant effects of silver, gold, and zinc oxide nanoparticles on male mice in in vivo condition |
| - | in-vivo, | Nor, | NA |
| 1909- | AgNPs, | The Antibacterial Drug Candidate SBC3 is a Potent Inhibitor of Bacterial Thioredoxin Reductase |
| - | in-vivo, | Nor, | NA |
| 1905- | AgNPs, | Evaluation of the effect of silver and silver nanoparticles on the function of selenoproteins using an in-vitro model of the fish intestine: The cell line RTgutGC |
| - | in-vivo, | Nor, | NA |
| 5236- | AgNPs, | Adaptive regulations of Nrf2 alleviates silver nanoparticles-induced oxidative stress-related liver cells injury |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Nor, | L02 |
| 5239- | AgNPs, | NOX4- and Nrf2-mediated oxidative stress induced by silver nanoparticles in vascular endothelial cells |
| - | in-vitro, | Nor, | HUVECs |
| 4402- | AgNPs, | Enhancement of Triple-Negative Breast Cancer-Specific Induction of Cell Death by Silver Nanoparticles by Combined Treatment with Proteotoxic Stress Response Inhibitors |
| - | in-vitro, | BC, | BT549 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 4400- | AgNPs, | Rad, | Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vivo, | BC, | MDA-MB-231 |
| 4393- | AgNPs, | Nanotoxic Effects of Silver Nanoparticles on Normal HEK-293 Cells in Comparison to Cancerous HeLa Cell Line |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | HEK293 |
| 4382- | AgNPs, | Silver nanoparticles induce cytotoxicity by a Trojan-horse type mechanism |
| - | in-vitro, | Nor, | RAW264.7 |
| 4411- | AgNPs, | Eco-friendly synthesis of silver nanoparticles using Anemone coronaria bulb extract and their potent anticancer and antibacterial activities |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Nor, | HEK293 |
| 4431- | AgNPs, | doxoR, | Oxidative Stress-Induced Silver Nano-Carriers for Chemotherapy |
| - | in-vitro, | BC, | 4T1 | - | in-vivo, | BC, | 4T1 | - | in-vitro, | Nor, | 3T3 |
| 4360- | AgNPs, | Silver Nanoparticles as Real Topical Bullets for Wound Healing |
| - | Study, | Nor, | NA |
| 4430- | AgNPs, | Evaluation of the Genotoxic and Oxidative Damage Potential of Silver Nanoparticles in Human NCM460 and HCT116 Cells |
| - | in-vitro, | Colon, | HCT116 | - | in-vitro, | Nor, | NCM460 |
| 4433- | AgNPs, | Advancements in metal and metal oxide nanoparticles for targeted cancer therapy and imaging: Mechanisms, applications, and safety concerns |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Nor, | L02 |
| - | vitro+vivo, | Nor, | NA |
| 4447- | AgNPs, | Anti-inflammatory action of silver nanoparticles in vivo: systematic review and meta-analysis |
| - | Review, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:49 Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid